- Home
- CSR vs SANA Comparison
CSR vs SANA Comparison
Compare CSR & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- SANA
- Stock Information
- Founded
- CSR 1970
- SANA 2018
- Country
- CSR United States
- SANA United States
- Employees
- CSR N/A
- SANA N/A
- Industry
- CSR Real Estate Investment Trusts
- SANA Medicinal Chemicals and Botanical Products
- Sector
- CSR Real Estate
- SANA Health Care
- Exchange
- CSR Nasdaq
- SANA Nasdaq
- Market Cap
- CSR 965.4M
- SANA 983.4M
- IPO Year
- CSR N/A
- SANA 2021
- Fundamental
- Price
- CSR $58.68
- SANA $4.12
- Analyst Decision
- CSR Buy
- SANA Strong Buy
- Analyst Count
- CSR 7
- SANA 6
- Target Price
- CSR $68.57
- SANA $8.00
- AVG Volume (30 Days)
- CSR 116.0K
- SANA 3.8M
- Earning Date
- CSR 10-27-2025
- SANA 11-07-2025
- Dividend Yield
- CSR 5.22%
- SANA N/A
- EPS Growth
- CSR N/A
- SANA N/A
- EPS
- CSR N/A
- SANA N/A
- Revenue
- CSR $267,076,000.00
- SANA N/A
- Revenue This Year
- CSR $5.34
- SANA N/A
- Revenue Next Year
- CSR $2.80
- SANA N/A
- P/E Ratio
- CSR N/A
- SANA N/A
- Revenue Growth
- CSR 3.44
- SANA N/A
- 52 Week Low
- CSR $52.76
- SANA $1.26
- 52 Week High
- CSR $75.92
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- CSR 51.01
- SANA 68.83
- Support Level
- CSR $57.62
- SANA $3.28
- Resistance Level
- CSR $59.81
- SANA $3.58
- Average True Range (ATR)
- CSR 1.35
- SANA 0.23
- MACD
- CSR -0.05
- SANA 0.11
- Stochastic Oscillator
- CSR 52.79
- SANA 90.98
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.